Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Regeneron profit beats, expects early results from COVID-19 trials in September

share with twitter share with LinkedIn share with facebook
08/05/2020 | 06:36am EDT

Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, helped by higher sales of its eczema drug Dupixent and said it expects initial data from ongoing trials of its COVID-19 antibody cocktail next month.

The company's shares were up 3% at $668.35 before the bell.

Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters.

REGN-COV2 is already being assessed in late-stage human studies and the company said on Wednesday it expects early data from the trials next month.

Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron's blockbuster drug Eylea.

U.S. sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.11 billion from $1.16 billion, but came in above Wall Street estimates of $1.06 billion, according to brokerage Piper Sandler.

"We think demand concerns were overblown, as the franchise performed despite pandemic headwinds (and competitors discussing segment weakness)," Credit Suisse analyst Evan Seigerman said.

Weakness in Eylea sales was offset by a nearly 70% jump in sales of Dupixent, made in collaboration with Sanofi.

On an adjusted basis, the company earned $7.16 per share, handily beating estimates of $5.98, according to Refinitiv IBES data.

Revenue rose 23.7% to $1.95 billion, higher than estimates of $1.74 billion.

Regeneron also recorded revenue in the quarter related to funding from the U.S. government to support development of its Ebola treatment and antibodies for the treatment of COVID-19.

(Reporting by Dania Nadeem and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -11.63% 47.195 Delayed Quote.-35.30%
CREDIT SUISSE GROUP AG -0.67% 9.176 Delayed Quote.-29.46%
PIPER SANDLER COMPANIES -1.41% 71.97 Delayed Quote.-8.68%
REGENERON PHARMACEUTICALS -0.76% 556.2186 Delayed Quote.49.08%
SANOFI 0.05% 85.19 Real-time Quote.-4.79%
share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09:48aWALL STREET STOCK EXCHANGE : U.S. Stocks Open Higher to Start New Quarter
09:18aBAYER : to accelerate transformation to address challenging market environment a..
07:45aBAYER : Correction to Bayer Article on Sept. 30
07:30aGLOBAL MARKETS LIVE: No Moderna vaccine before the election
07:16aNEWS HIGHLIGHTS : Top Company News of the Day
07:09aBAYER : Bleaker profit outlook at Bayer turns into reckoning over Monsanto
06:22aU.S. Stock Futures Rally Ahead of Economic Data
05:58aBAYER AG : Barclays reiterates its Buy rating
05:37aU.S. Stock Futures Rally Ahead of Economic Data
05:20aBAYER AG : UBS reaffirms its Buy rating
More news
Sales 2020 43 218 M 50 827 M 50 827 M
Net income 2020 -3 346 M -3 935 M -3 935 M
Net Debt 2020 32 613 M 38 355 M 38 355 M
P/E ratio 2020 -14,6x
Yield 2020 5,21%
Capitalization 52 373 M 61 500 M 61 593 M
EV / Sales 2020 1,97x
EV / Sales 2021 1,90x
Nbr of Employees 101 168
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 75,65 €
Last Close Price 53,31 €
Spread / Highest target 106%
Spread / Average Target 41,9%
Spread / Lowest Target -13,7%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-35.30%61 500
JOHNSON & JOHNSON2.06%391 975
ROCHE HOLDING AG0.37%293 803
MERCK & CO., INC.-8.80%209 801
PFIZER, INC.-7.68%203 937
NOVARTIS AG-13.05%191 928